And Platinum Pharmaceuticals completed the B-plus round of financing of $75 million and C round of financing of $100 million, at the Cell Engager Summit to show its BCMAxCD3 dual specific antibodies.

Founded in December 2016, Harbor BioMed has grown rapidly, completing $75 million in B-plus financing and $102.8 million in round C financing this year.
recent Hong Kong IPO prospectos were also made public, spending $15.2m on research and development in the first half of this year.
Photo Source: and Platinum Pharmaceuticals Prospectine Source: And Platinum Pharmaceuticals Prospects at Cell Engager Summit 2020, and Platinum Pharmaceuticals showcasing its new dual-specific antibody BCMAxCD3 (HBM7020).
HBM7020 is based on its HBICETM platform and has significant tumor lethality and minimal cytokine response, which can be converted into relatively effective and safe treatments.
B cell mature antigen (BCMA) is a highly expressed surface marker on malignant plasma cells in patients with multiple myeloma (MM) and has been recognized as an ideal target for T-cell redirect therapy.
currently, treatments for BCMA are still unresponsive and relapsed in some patients. limitations such as fast, toxicity caused by cytokine release syndrome (CRS) and short half-life.
HBM7020 can overcome certain limitations and become a new generation therapy for multiple myeloma, selectively removing BCMA-positive MM cells with less cytokine release.
HBM7020 is designed in the form of a "2-plus", with an anti-CD3 binding domain used to activate T-cell activity and two anti-BCMA binding domains to improve the selectivity of BCMA-positive MM cells.
compared to rival Regeneron's BCMAxCD3 dual-specific antibodies, HBM7020 effectively kills BCMA-positive MM cells and reduces the risk of CRS (cytokine release syndrome).
BCMAxCD3 dual-specific antibody for regenerative cells (Image Source: Guangming)